The European Union represents an important marketing opportunity in terms of dimensions thanks to the existing common regulations among countries via the centralized procedures. The pharmaceutical regulation in this region is governed by supranational bodies, such as the EMA and its working parties and associate partner authorities.
To succeed in the approach to these entities, a correct designation of the product and a detailed strategy about the best way to contact, timings, meeting preparations, obtention of proper advice, management of CTAs, among others, are crucial to achieve an accelerated approval.
Europe Solutions
Schedule a free meeting!
Discuss your case with our experts and receive a valuable feedback
Share
Why Asphalion?
With 20+ years track record in handling submissions, Asphalion provides reliable support for all type of regulatory procedures in Europe. We provide regulatory strategy to anticipate any potential hurdle, coordinate your submissions and liaise with European agencies until the approval of the Marketing Authorisation.
Main benefits
Asphalion has large experience in writing, submitting and updating all types of technical dossiers specified for each product type including:
Furthermore, Asphalion has a proven track record and experience in following tracks, timings and standard formats in centralized submission procedures involving all intervenient regulatory entities.
Related Resources
Highlights video
Highlights video
Highlights video
Highlights video
Highlights video
Highlights video
IND preparation and submission business case: A small European biotech company focused on drug discovery and development interested in engaging with the FDA.
Asphalion contributions to the fight against COVID-19
A guide to have an overview of regional submissions requirements
(CTR) No 536/2014
A network of qualified partners that allows ASPHALION to provide pharmacovigilance services throughout Europe
Scientific & Regulatory Affairs Support during development of ATMPs & Biologics
We are proud to share that the KeratoPrinter project was featured at the RAPS EuroConvergence 2026. During the event, our team had the opportunity to present some of the Horizon
A relevant development for the medtech industry: today, 28 April 2026, the EMA has launched its pilot programme to support developers of Breakthrough Devices (BtX) under the MDR and IVDR.The
At Asphalion, we’re excited to be part of key events, conferences, and summits throughout 2026—great opportunities to connect, exchange insights, and collaborate with leaders across healthcare and medical devices.
Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts.
We will be happy to assist you!
